Flow-chart of patients population.

<p>Flow-chart of patients population.</p

ALK FISH examples.

<p>Gain of ALK GCN (including both low and high genomic gain) was defined as a mean of 3 to 5 fusion signals in ≥10% of cells (Figure on right). Disomic cells are shown in Figure on left.</p

Overall survival analysis.

<p>Kaplan-Meier curves for overall survival according to ALK status: increase of gene copy number vs. disomic status.</p

MOESM3 of GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study

Additional file 3: Figure S2. Comparison of Kaplan-Meier curves for progression-free survival according to GNAS mutational status in both the prospective (metronomic capecitabine and bevacizumab) and the retrospective cohort (FOLFOX-4)

MOESM2 of GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study

Additional file 2: Figure S1. Comparison of Kaplan-Meier curves for progression-free survival according to GNAS mutational status in the retrospective cohort (FOLFOX-4)